World Library  
Flag as Inappropriate
Email this Article
 

NovaBay Pharmaceuticals

NovaBay Pharmaceuticals,Inc.
Public
Traded as NYSE MKT: NBY
Industry Health care
Biotechnology
Founded 2000
Founder Ron Najafi
Headquarters Emeryville, California, United States
Key people
Ron Najafi, Ph.D., CEO
Tom Paulson, M.B.A., CFO
Keith R. Bley, Ph.D., Sr. VP of Product Development
Russell Hoon, Sr. VP of Advanced Wound Care
David Stroman, Ph.D., Sr. VP, Ophthalmology
Roy Wu, M.B.A., Sr. VP, Business Development
Glenn Moro,VP, Sales and Marketing Avenova
Number of employees
26 (2013)
Website novabay.com

NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on developing novel, fast-acting, synthetic anti-infectives compounds. These compounds are designed to mimic the body's defense system against infection. The company is currently focused on products for the eye care market. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis.[1] and NeutroPhase, used in treatment of Necrotizing Fasciitis[2][3]

Contents

  • History 1
  • Corporate Governance 2
  • Products 3
    • Products on the market 3.1
    • Products under development 3.2
  • References 4
  • External links 5

History

NovaBay Pharmaceuticals, Inc. was founded by Ron Najafi, an organic chemist who had previously worked for several pharmaceutical, chemical and biotech companies in the U.S. In 1996 he with the help of his wife Kelly Farhangi Najafi founded CP Lab Safety to market a product to trap emissions from open waste containers in laboratories. When running CP Lab Safety, Najafi became intrigued by hypochlorous acid, an antimicrobial substance produced by White Blood Cells during oxidative burst. HOCl and other chlorine-containing chemicals fight invading microbes. These natural substances rapidly oxidize the cell walls of bacteria and the protein coats of viruses, rendering them inactive.

Najafi started NovaBay Pharmaceuticals in 2000 to create a stable version of HOCl.[4]

Najafi, chemistry Nobel Laureate Herbert C. Brown, and Purdue University Professor Dale Margerum recruited Dr. Lu Wang to NovaBay, where she is now Director of Product Development. She was able to develop the stable version of pure hypochlorous acid, without bleach impurities, which became NovaBay’s first product, NeutroPhase[5] and cleared by the Food and Drug Administration in 2010. The product successfully treats a variety of chronic non-healing wounds without the use of standard antibiotics. NovaBay announced two new products named CelleRx™ for Plastic Surgery and i-Lid™ Cleanser (Now Avenova) that was cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis.

Corporate Governance

As of September 30, 2013, the members of the board of directors of NovaBay Pharmaceuticals were: Ron Najafi, Ph.D., Chairman and CEO, Charles J. Cashion, Paul E. Freiman, Gail Maderis, T. Alex McPherson, M.D., Ph.D., Massimo Radaelli, Ph.D., Mark Sieczkarek and Tony Wicks.

Products

Products on the market

Avenova (formerly known as i-Lid Cleanser) [6] NeutroPhase [7] CelleRx, for Plastic Surgery

Products under development

NovaBay developed a method for making a stable pure form of hypochlorous acid (HOCl), a substance produced by the immune system as an effective first defense against microbial invaders. The company calls their proprietary formulation Neutrox. The company's chemists also created a related family of compounds which the company calls Aganocides.

The company is currently developing compounds with anti-bacterial and anti-viral action. Potential applications include flesh-eating disease, problems related to in-dwelling urinary catheters, and common eye conditions. Compounds are also being developed for the veterinary market.[8]

References

  1. ^
  2. ^
  3. ^
  4. ^
  5. ^
  6. ^ NovaBay’s new Advanced i-Lid Cleanser has been Cleared by the FDA for Cleaning, Removing Debris and Microbes from the Skin around the Eyes, the Eyelids and Eyelashes eyelid and lash cleansing as part of a regimen for Blepharitis."
  7. ^
  8. ^

External links

  • .com.novabaywww
  • .com.neutrophasewww
  • .com.avenovawww
  • .com.avenova.doctorswww
  • .com.cellerxwww
  • NovaBay Pharmaceuticals, Inc., "The New York Times"
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.